BACKGROUND: Integrins are involved in tumour progression and metastasis, and differentially expressed on colorectal cancer (CRC) cells. Abituzumab (EMD 525797), a humanised monoclonal antibody targeting integrin αν heterodimers, has demonstrated preclinical activity. This trial was designed to assess the tolerability of different doses of abituzumab in combination with cetuximab and irinotecan (phase I) and explore the efficacy and tolerability of the combination versus that of cetuximab and irinotecan in patients with metastatic CRC (mCRC) (phase II part). METHODS: Eligible patients had KRAS (exon 2) wild-type mCRC and had received prior oxaliplatin-containing therapy. The trial comprised an initial safety run-in using abituzumab doses up to 1000 mg combined with a standard of care (SoC: cetuximab plus irinotecan) and a phase II part in which patients were randomised 1 : 1 : 1 to receive abituzumab 500 mg (arm A) or 1000 mg (arm B) every 2 weeks combined with SoC, or SoC alone (arm C). The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included overall survival (OS), response rate (RR) and tolerability. Associations between tumour integrin expression and outcomes were also assessed. RESULTS: Phase I showed that abituzumab doses up to 1000 mg were well tolerated in combination with SoC. Seventy-three (arm A), 71 (arm B) and 72 (arm C) patients were randomised to the phase II part. Baseline characteristics were balanced. PFS was similar in the three arms: arm A versus SoC, hazard ratio (HR) 1.13 [95% confidence interval (CI) 0.78-1.64]; arm B versus SoC, HR 1.11 (95% CI 0.77-1.61). RRs were also similar. A trend toward improved OS was observed: arm A versus SoC, HR 0.83 (95% CI 0.54-1.28); arm B versus SoC, HR 0.80 (95% CI 0.52-1.25). Grade ≥3 treatment-emergent adverse events were observed in 72%, 78% and 67% of patients. High tumour integrin αvβ6 expression was associated with longer OS in arms A [HR 0.55 (0.30-1.00)] and B [HR 0.41 (0.21-0.81)] than in arm C. CONCLUSION: The primary PFS end point was not met, although predefined exploratory biomarker analyses identified subgroups of patients in whom abituzumab may have benefit. The tolerability of abituzumab combined with cetuximab and irinotecan was acceptable. Further study is warranted. CLINICALTRIALS.GOV IDENTIFIER: NCT01008475.

City Clinical Oncology Dispensary St Petersburg

Department of Comprehensive Cancer Care Masarykuv Onkologicky Ustav Brno Czech Republic

Department of Digestive Oncology University Hospital Gasthuisberg Leuven and KULeuven Leuven Belgium

Department of Hematology Oncology Cancer Center Heilbronn Franken Heilbronn

Department of Oncology Hematology University Hospital Hamburg Hamburg Germany

Department of Oncology Horovice Czech Republic

Department of Oncology Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet Szolnok Hungary

Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc

GOU VPO St Petersburg SMA n a Mechnikov Federal Agency of Healthcare St Petersburg

Medical Clinic 1 Prosper Hospital Recklinghausen

Merck KGaA Darmstadt Germany

S 1 Russian Cancer Research Center Moscow Russia

University Hospital Marques de Valdecilla Santander Spain

Vall d'Hebron University Hospital and Institute of Oncology Universitat Autònoma de Barcelona Barcelona Spain

Citace poskytuje Crossref.org

Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01008475